Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PPM1B | O75688 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.41 |
| ▸ | LGMN | Q99538 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2432866 | 1.00 | MAPT (0.47) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2432868 | 1.00 | MAPT (0.47) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL103276 | 0.87 | MAPT (0.51) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16089711 | 0.85 | MAPT (0.50) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4251803 | 0.83 | MAPT (0.49) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16841463 | 0.83 | MAPT (0.49) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4251805 | 0.83 | MAPT (0.49) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15105909 | 0.82 | MAPT (0.45) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL18204623 | 0.82 | MAPT (0.45) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL18204624 | 0.82 | MAPT (0.45) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086966-B1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
| WO-2008059042-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | EIF2AK2, HAVCR2, GTF3C2 | MAPT 3802/4885ALDH1A1 860/4885CYP3A4 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.